Inspire Medical Systems, Inc. Earnings Recaps
Q1 2026
May 5, 2026
Shares dropped 14.9% following the quarter as investors reacted negatively to a revised full-year revenue outlook amid ongoing coding and reimbursement challenges, compounded by headwinds from the new WISER prior authorization program.
Key takeaways
- Revenue growth and adjusted operating income improved versus prior year, but underlying operational challenges persist.
- Significant coding and reimbursement uncertainties remain, particularly for the Inspire V system, with only partial short-term solutions in place.
- Medicare’s new C-code for Inspire V provides some clarity, but broader commercial payer coding remains inconsistent, requiring manual reviews and prior authorizations.
- The WISER program introduced prior authorization delays in six states, adversely impacting first-quarter revenue and creating ongoing headwinds.
- Management is increasing customer support and education to improve prior authorization success and expects coding and reimbursement trends to stabilize later in the year.
Q3 2025
Nov 6, 2025
Inspire Medical Systems delivered robust third-quarter results, with revenue rising 10% year-over-year to $224.5 million, supported by strong patient adoption and favorable reimbursement developments.
Key takeaways
- Operating income reached $9.6 million, with earnings per share guidance upgraded to $0.90–$1.00, reflecting improved cost discipline and revenue growth.
- Physician training for the Inspire V system is over 98% complete, and contracting is over 90% finalized, positioning the company for a successful product launch.
- Recent clinical studies highlighted Inspire’s effectiveness in reducing long-term cardiovascular risks in OSA patients, reinforcing the company's commitment to innovation and patient outcomes.